Anavex Life Sciences Corp (AVXL)

[Jonjones325]

"Full genomic analysis of ANAVEX®2-73-PDD-001 Phase 2 study in
patients with Parkinson’s Disease Dementia (PDD) assessed biomarkers
of response exploring potential for a Precision Medicine approach"

Not sure how this statement leads you to believe another P3 for Alz may be required. Isn’t it enough to have our one decent sized trial beat the SOC with biomarkers and gene upregulation proof of our MOA? If anything it seems to strengthen our case for a P4 rather than another P3.

I may agree with another P3 if we didn’t have the outstanding safety profile

On another note, this publication coupled with our educational videos make a perfect set up to release the PDD OLE data.

It shows we are on the right track, hitting targets that are confirming our results.

Hopefully Missling capitalizes on this momentum and raises fund’s opportunistically just in case.

This publication IMO allows us to move forward with the Fragile X and other undisclosed trial and may be the piece they have been waiting for.